We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

52 hedge funds and large institutions have $241M invested in Aspire Biopharma in 2022 Q2 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.07% more ownership

Funds ownership: 0% → 0.07% (+0.07%)

Holders
52
Holders Change
+52
Holders Change %
–
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
52
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$21M
2
GCL
Glazer Capital LLC
New York
+$20.4M
3
SCM
Saba Capital Management
New York
+$19.6M
4
AA
AQR Arbitrage
Connecticut
+$13.4M
5
HCM
Highbridge Capital Management
New York
+$11.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
26
Radcliffe Capital Management
Pennsylvania
$2.99M +$2.99M +250 New
UOC
27
UBS O'Connor
Illinois
$2.52M +$2.53M +211 New
WA
28
Whitebox Advisors
Minnesota
$2.5M +$2.49M +208 New
Hudson Bay Capital Management
29
Hudson Bay Capital Management
Connecticut
$2M +$2M +167 New
KL
30
KIM LLC
Kansas
$2M +$2M +167 New
WAM
31
Weiss Asset Management
Massachusetts
$2M +$2M +167 New
WP
32
Woodline Partners
California
$2M +$2M +167 New
CCM
33
CAAS Capital Management
New York
$1.5M +$1.5M +125 New
PMAM
34
Picton Mahoney Asset Management
Ontario, Canada
$1.5M +$1.5M +125 New
CSS
35
Cubist Systematic Strategies
Connecticut
$1.22M +$1.22M +102 New
OCM
36
Oaktree Capital Management
California
$998K +$994K +83 New
GT
37
Glenmede Trust
Pennsylvania
$985K +$982K +82 New
KKRC
38
Kohlberg Kravis Roberts & Co
New York
$749K +$755K +63 New
CH
39
CVI Holdings
Delaware
$499K +$503K +42 New
ECU
40
Eisler Capital (UK)
United Kingdom
$499K +$503K +42 New
MTCM
41
Mint Tower Capital Management
Netherlands
$499K +$503K +42 New
UBS Group
42
UBS Group
Switzerland
$487K +$491K +41 New
DAM
43
DLD Asset Management
New York
$432K +$431K +36 New
CM
44
Cohanzick Management
New York
$373K +$371K +31 New
SIA
45
Schechter Investment Advisors
Michigan
$295K +$299K +25 New
WC
46
Wealthspring Capital
New York
$295K +$299K +25 New
Citigroup
47
Citigroup
New York
$278K +$275K +23 New
PI
48
PEAK6 Investments
Illinois
$250K +$252K +21 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$215K +$216K +18 New
OMC
50
Old Mission Capital
Illinois
$166K +$168K +14 New
1
2
3

ASBP Hedge Fund Activity: Q2 2022 in Review

52 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q2 2022, worth a combined $241M.

Buyers outnumbered sellers: 52 funds opened new ASBP positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $21M.

  • 52 institutional investors held Aspire Biopharma (ASBP) as of Q2 2022, up from 0 in Q1 2022.
  • Funds reported $241M of Aspire Biopharma stock for Q2 2022.
  • 52 funds opened new Aspire Biopharma positions in Q2 2022 and 0 closed out, a net change of +52 holders.
  • The largest Aspire Biopharma buyer in Q2 2022 was Adage Capital Partners, an estimated $21M added.

Based on aggregated 13F filings for Q2 2022.